Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

EUGIA

Drug and asset intelligence for EUGIA with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Stage
Development stage unavailable

Sponsor company

Eugia Pharma →

Mechanism of action

Chemotherapy

Recent signals(5)

RegulatoryJuly 31, 2026

EUGIA PHARMA's Tranexamic Acid Supplement Receives FDA AP Status

EUGIA PHARMA's application for a supplement of Tranexamic Acid has received FDA approval status.

RegulatoryJuly 30, 2026

EUGIA PHARMA's Lenalidomide ANDA213885 Receives AP Status from FDA

EUGIA PHARMA's application for Lenalidomide (ANDA213885) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 20, 2026

Eugia Pharma's Methotrexate Sodium ANDA210454 Receives AP Status

Eugia Pharma's application for Methotrexate Sodium (ANDA210454) has received an Abbreviated Approval (AP) status from the FDA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Antifibrinolytic →
Hematology →
Hormonal Therapy →
Oncology →
Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

RegulatoryJuly 19, 2026

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

Eugia Pharma has submitted a supplemental application for Zoledronic Acid under ANDA209125, currently under standard review.

RegulatoryJuly 7, 2026

Eugia Pharma's Tranexamic Acid Supplement Application Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for Eugia Pharma's Tranexamic Acid.